Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Chinese Patients With Refractory CML or Ph+ ALL
NCT04233346Phase 2Completed
- Sponsor
- Otsuka Holdings
- Start
- Jul 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ponatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Otsuka Holdings. Primary endpoints: Major Cytogenetic Response at 12 months and Major Hematologic Response at 6 months. Started Jul 2020; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04233346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233346.